Pancreatic neuroendocrine tumors (pNETs) are rare neoplasms originating from the endocrine islet cells of the pancreas. According to Alexandra Helbing et al., 2025, it accounts for approximately 1% to 2% of all pancreatic cancers. With rising incidence and improved diagnostic techniques, there is a growing focus on the development of targeted therapies and novel treatment approaches. According to the pancreatic neuroendocrine tumors pipeline analysis by Expert Market Research, the market is expected to witness steady growth in the coming years. One promising therapeutic in the pipeline is Surufatinib, which targets multiple receptors involved in tumor angiogenesis and immune evasion, showing potential in advanced pNET cases.
Major companies involved in the pancreatic neuroendocrine tumors pipeline analysis include RayzeBio, Inc., TaiRx, Inc, and others.
Leading drugs currently in the pipeline include RYZ101, CVM-1118, and others.
Rising clinical trials of targeted therapies, increasing FDA fast-track designations, and growing focus on peptide receptor radionuclide therapy (PRRT) are accelerating development in the pancreatic neuroendocrine tumors drug pipeline.
The Pancreatic Neuroendocrine Tumors Pipeline Analysis Report by Expert Market Research gives comprehensive insights into pancreatic neuroendocrine tumors therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for pancreatic neuroendocrine tumors. The pancreatic neuroendocrine tumors report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The pancreatic neuroendocrine tumors pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with pancreatic neuroendocrine tumors treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to pancreatic neuroendocrine tumors.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Pancreatic neuroendocrine tumors (PNETs) are rare growths that originate from hormone-producing cells of the pancreas. They often grow more slowly than typical pancreatic cancers but can become aggressive and spread. PNETs develop when endocrine cells mutate and multiply uncontrollably, forming tumors that may release excess hormones, leading to a range of symptoms depending on the hormone produced.
Pancreatic neuroendocrine tumors are treated through surgery, targeted therapy, chemotherapy, or hormone therapy, depending on tumor type, size, spread, and patient condition. Multidisciplinary care is crucial for effective management. In March 2025, the U.S. Food and Drug Administration approved CABOMETYX® (cabozantinib) as a targeted treatment for adults with previously treated, well-differentiated pancreatic neuroendocrine tumors, significantly extending progression-free survival.
According to Alexandra Helbing et al., 2025, pancreatic neuroendocrine tumors (pNETs) account for 1% to 2% of all pancreatic neoplasms and approximately 7% of neuroendocrine tumors. The annual incidence is estimated at up to 1 in 100,000 individuals, with rates rising due to improved diagnostic methods. pNETs are slightly more common in men and are typically diagnosed between the ages of 55 and 60. Nonfunctional types comprise 60% to 90% of cases.
This section of the report covers the analysis of pancreatic neuroendocrine tumors drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The pancreatic neuroendocrine tumors pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total pancreatic neuroendocrine tumors clinical trials, with 54%, highlighting a significant concentration of mid-stage clinical trials. Phase I follows at 30%, suggesting active early-stage research. Phase III makes up nearly 10%, indicating a steady transition toward late-stage development. This distribution underscores a well-rounded pipeline with a strong emphasis on future treatment development.
The drug molecule categories covered under the pancreatic neuroendocrine tumors pipeline analysis include small molecules, monoclonal antibodies, peptides, gene therapies, and immunotherapies. The pancreatic neuroendocrine tumors report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for pancreatic neuroendocrine tumors. Hormone-based and radioligand therapies are gaining momentum in the pancreatic neuroendocrine tumors drug pipeline. For instance, a new trial is evaluating the combination of fulvestrant, an estrogen receptor antagonist, with 177Lu-DOTATATE, a peptide receptor radionuclide therapy. This investigational approach aims to enhance tumor response by disrupting hormone signaling and delivering targeted radiation to neuroendocrine tumor cells.
The EMR report for the pancreatic neuroendocrine tumors pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed pancreatic neuroendocrine tumors therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in pancreatic neuroendocrine tumors clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for pancreatic neuroendocrine tumors. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of pancreatic neuroendocrine tumors drug candidates.
RYZ101, developed by RayzeBio, Inc., is a first-in-class alpha-emitting radiopharmaceutical targeting SSTR2+ tumors. It is undergoing a Phase 1b/3 trial. The trial is evaluating its safety, efficacy, and pharmacokinetics in patients with inoperable, well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that are progressing after 177Lu-SSA therapy. The study is comparing RYZ101 with standard-of-care treatments.
CVM-1118 is a novel small-molecule drug sponsored by TaiRx, Inc., currently undergoing a Phase II trial to evaluate its efficacy in patients with advanced pancreatic neuroendocrine tumors (PNETs). Acting as a TRAP1 mitochondrial protein inhibitor, CVM-1118 promotes apoptosis and inhibits vasculogenic mimicry. The study is focusing on its anticancer potential and progression-free survival outcomes.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Pancreatic Neuroendocrine Tumors Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for pancreatic neuroendocrine tumors. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into pancreatic neuroendocrine tumors collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share